Russel Burge

8.4k citations

155 papers · 6.2k indexed · 1 hit paper · h-index 31

Impact in

Orthopedics and Sports Medicine top 0.1%
- Bone health and osteoporosis research
Dermatology top 0.5%
- Dermatology and Skin Diseases

Papers in

Dermatology 53
- Dermatology and Skin Diseases 47
Orthopedics and Sports Medicine 40
- Bone health and osteoporosis research 40

Co-authors: Alison B. King Anna N.A. Tosteson Daniel H. Solomon John B. Wong Bess Dawson‐Hughes Trong Kim Le John L. Mershon Robert Lindsay
Journals: Dermatology and Therapy (19 papers)Osteoporosis International (15 papers)Journal of the American Academy of Dermatology (14 papers)Journal of the European Academy of Dermatology and Venereology (8 papers)Journal of Dermatological Treatment (7 papers)
Partner nations: United States United Kingdom Canada

In The Last Decade

Russel Burge

149 papers receiving 6.1k citations

Hit Papers

align trajectories log scale

Incidence and Economic Burden of Osteoporosis-Related Fractures in the United States, 2005–2025 2006 · 3.1k citations

Peers

Countries citing papers authored by Russel Burge

Since Specialization

Citations

This map shows the geographic impact of Russel Burge's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Russel Burge with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Russel Burge more than expected).

Fields of papers citing papers by Russel Burge

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Russel Burge. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Russel Burge. The network helps show where Russel Burge may publish in the future.

Co-authors

The 25 scholars most cited alongside Russel Burge, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Russel Burge Line = papers co-authored together Russel Burge links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis Journal of Dermatological Treatment ·Andrew Blauvelt, Leon Kircik, Todd Schlesinger, Evangeline Pierce, Russel Burge, M. Behling, Amber Reck Atwater, Hany Elmaraghy, April W. Armstrong	2025	2
2	Exploring racial and ethnic disparities in the hidradenitis suppurativa patient disease journey: Results from a real‐world study in Europe and the USA The Journal of Dermatology ·Tarannum Jaleel, Beth Mitchell, Russel Burge, Andrea A. Cohee, Hayley Wallinger, Isabel Truman, Aaron Keal, Chloe Middleton‐Dalby, Sophie Barlow, Dipak Patel	2024	0
3	Achievement of the National Psoriasis Foundation Treatment Treat-to-Target Goals in the US Ixekizumab Customer Support Program SKIN The Journal of Cutaneous Medicine ·Alice B. Gottlieb, Russel Burge, William N. Malatestinic, Baojin Zhu, Yunyang Zhao, Julie McCormack, Miriam Kimel, Meghan Feely, Joseph F. Merola	2023	2
4	43015 Ixekizumab real-world effectiveness at 24 weeks in patients with psoriasis: Data from the United States Taltz Customer Support Program Journal of the American Academy of Dermatology ·Alice B. Gottlieb, Russel Burge, William N. Malatestinic, Baojin Zhu, Jiaying Guo, Yunyang Zhao, Julie McCormack, Miriam Kimel, Meghan Feely, Joseph F. Merola	2023	1
5	Annual indirect costs savings in patients with episodic or chronic migraine: a post-hoc analysis of phase 3 galcanezumab clinical trials in the United States Journal of Medical Economics ·Oralee J. Varnado, Wenyu Ye, Xiaojuan Mi, Russel Burge, Jerry Hall	2023	2
6	Development of Psoriasis Assessment Tools Among Patients in the CorEvitas Psoriasis Registry PubMed ·Wayne Gulliver, Kyoungah See, Baojin Zhu, Bruce W. Konicek, Ryan W. Harrison, Robert R. McLean, Samantha J. Kerti, Russel Burge, Craig L. Leonardi	2023	0
7	Treatment Goals for Psoriasis as Measured by Patient Benefit Index: Results of a National Psoriasis Foundation Survey Advances in Therapy ·April W. Armstrong, Emily Edson‐Heredia, Baojin Zhu, Russel Burge, Stacie Bell, J. Crowley, Stacy Smith	2022	8
8	Healthcare resource utilization and costs among patients with psoriasis treated with ixekizumab or adalimumab over 2 years of follow-up in real-world settings Journal of Medical Economics ·Andrew Blauvelt, Nianwen Shi, Mwangi J. Murage, Scott A. Kern, Najwa Somani, Russel Burge, Terri Ridenour, Carolyn R. Lew, Nicole M. Zimmerman, Baojin Zhu	2022	1
9	Treatment Persistence of Ixekizumab in Adults with Moderate-to-Severe Plaque Psoriasis Participating in the Canadian Patient Support Program Dermatology and Therapy ·Wayne Gulliver, Melinda Gooderham, Baojin Zhu, Christian Jossart, Sonia Montmayeur, Russel Burge, Catherine Reed	2022	5
10	Dermatologist and Patient Perceptions of Treatment Success in Alopecia Areata and Evaluation of Clinical Outcome Assessments in Japan Dermatology and Therapy ·Jake Macey, Helen Kitchen, Natalie V. J. Aldhouse, Russel Burge, Emily Edson‐Heredia, Jill Shwed McCollam, Yoshitaka Isaka, Hitoe Torisu‐Itakura	2021	16
11	Cost-Effectiveness of Baricitinib Compared With Standard of Care: A Modeling Study in Hospitalized Patients With COVID-19 in the United States Clinical Therapeutics ·Robert L. Ohsfeldt, Kari Kelton, Tim Klein, Mark Belger, Patrick L. Mc Collam, Theodore E. Spiro, Russel Burge, Neera Ahuja	2021	10
12	Dynamic Visual Representation of Clinical Efficacy of Ixekizumab in Psoriasis Dermatology and Therapy ·Jason E. Hawkes, Kyoungah See, Russel Burge, Stephanie Strakbein, Missy McKean-Matthews, Daniel Saure, Melinda Gooderham, Craig L. Leonardi	2021	1
13	A qualitative interview study to explore adolescents’ experience of alopecia areata and the content validity of sign/symptom patient‐reported outcome measures* British Journal of Dermatology ·Jake Macey, Helen Kitchen, Natalie V. J. Aldhouse, Emily Edson‐Heredia, Russel Burge, A Prakash, Brett King, Natasha Atanaskova Mesinkovska	2021	6
14	<p>Comparison of Real-World Treatment Patterns Among Psoriasis Patients Treated with Ixekizumab or Adalimumab</p> Patient Preference and Adherence ·Andrew Blauvelt, Nianwen Shi, Russel Burge, William N. Malatestinic, Chen‐Yen Lin, Carolyn R. Lew, Nicole M. Zimmerman, Orin M. Goldblum, Baojin Zhu, Mwangi J. Murage	2020	22
15	Comorbidities of alopecia areata: a population‐based cohort study Clinical and Experimental Dermatology ·Alexander Egeberg, Seth Anderson, Emily Edson‐Heredia, Russel Burge	2020	27
16	A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial* British Journal of Dermatology ·Andrew Blauvelt, C. Leonardi, Boni E. Elewski, Jeffrey Crowley, Lyn Guenther, Melinda Gooderham, Richard G. Langley, Ronald Vender, Andreas Pinter, C.E.M. Griffiths, Yayoi Tada, Hany Elmaraghy, Renata Gontijo Lima, Gaia Gallo, L. Renda, Russel Burge, S.Y. Park, Baojin Zhu, Kim Papp, (unknown)	2020	73
17	Understanding Treatment Preferences in Patients with Moderate to Severe Plaque Psoriasis in the USA: Results from a Cross-Sectional Patient Survey Dermatology and Therapy ·Joe Gorelick, David Shrom, Kiran Sikand, L. Renda, Russel Burge, C Dworkin, Craig Krebsbach, R.P. Patel, Chitra Karki, David Rosmarin	2019	33
18	Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis British Journal of Dermatology ·Caitriona Ryan, Alan Menter, Lyn Guenther, Andrew Blauvelt, Robert Bissonnette, K.A.P. Meeuwis, John Sullivan, Jennifer Clay Cather, Gil Yosipovitch, Alice B. Gottlieb, Joseph F. Merola, Kristina Callis Duffin, Scott Fretzin, Olawale Osuntokun, Russel Burge, April N. Naegeli, Fan Emily Yang, Chen‐Yen Lin, Kris Todd, Alison Potts Bleakman, (unknown)	2018	85
19	Cost Per Additional Responder Associated With Ixekizumab and Etanercept in the Treatment of Moderate-to-Severe Psoriasis. PubMed ·Feldman, Foster Sa, Bin Zhu, Russel Burge, Al Sawah S, Goldblum Om	2017	3
20	Characteristics of hip fracture patients with and without muscle atrophy/weakness: Predictors of negative economic outcomes Journal of Medical Economics ·Zhanglin Lin Cui, Michael J. Schoenfeld, Elizabeth Nicole Bush, Yi Chen, Russel Burge	2014	9

About Russel Burge

Russel Burge is a scholar working on Dermatology, Orthopedics and Sports Medicine, Immunology, Family Practice and Economics and Econometrics, having authored 155 papers that have together received 6.2k indexed citations. Recurring topics across this work include Psoriasis: Treatment and Pathogenesis (77 papers), Dermatology and Skin Diseases (47 papers), Bone health and osteoporosis research (40 papers), Health Systems, Economic Evaluations, Quality of Life (34 papers), Hip and Femur Fractures (29 papers), Pharmaceutical studies and practices (13 papers), Bone health and treatments (10 papers) and Asthma and respiratory diseases (9 papers). The work is most often cited by research in Orthopedics and Sports Medicine (2.9k citations), Dermatology (734 citations), Surgery (2.4k citations), Immunology (1.1k citations) and Oncology (1.1k citations). Russel Burge has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Alison B. King, Anna N.A. Tosteson, Daniel H. Solomon, John B. Wong, Bess Dawson‐Hughes, Trong Kim Le, John L. Mershon, Robert Lindsay, Alexander Egeberg and Andrew Blauvelt. Their work appears in journals such as Dermatology and Therapy, Osteoporosis International, Journal of the American Academy of Dermatology, Journal of the European Academy of Dermatology and Venereology and Journal of Dermatological Treatment.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact